MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

Search

Smith & Nephew PLC ADR

Atidarymo kaina

32.27 -4.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.96

Max

33.78

Pagrindiniai rodikliai

By Trading Economics

Pajamos

296M

Pardavimai

3B

P/E

Sektoriaus vid.

29.768

87.826

Dividendų pajamingumas

2.29

Pelno marža

9.895

Darbuotojai

17,000

EBITDA

723M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+4.65% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.29%

2.26%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

14B

Ankstesnė atidarymo kaina

36.63

Ankstesnė uždarymo kaina

32.27

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Smith & Nephew PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-12 23:54; UTC

Rinkos pokalbiai

CBA Could Underperform Again in 2026 -- Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2026-01-12 23:43; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-01-12 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026-01-12 21:56; UTC

Rinkos pokalbiai

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026-01-12 20:54; UTC

Uždarbis

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026-01-12 20:48; UTC

Rinkos pokalbiai

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026-01-12 20:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026-01-12 19:39; UTC

Rinkos pokalbiai

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 19:33; UTC

Rinkos pokalbiai

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026-01-12 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026-01-12 19:22; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026-01-12 18:21; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026-01-12 18:20; UTC

Įsigijimai, susijungimai, perėmimai

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026-01-12 18:19; UTC

Rinkos pokalbiai

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026-01-12 18:16; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026-01-12 18:01; UTC

Įsigijimai, susijungimai, perėmimai

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026-01-12 18:00; UTC

Rinkos pokalbiai

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC ADR Prognozė

Kainos tikslas

By TipRanks

4.65% į viršų

12 mėnesių prognozė

Vidutinis 35.75 USD  4.65%

Aukščiausias 37.5 USD

Žemiausias 34 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

26.64 / 28.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat